Assessing bias in administrative database studies of RotaTeq vaccine completion due to exclusion of subjects with incomplete follow-up

BACKGROUND: RotaTeq® pentavalent human rotavirus vaccine (RV5) is effective against rotavirus illness and rotavirus-related hospitalizations and death. Effectiveness depends on adherence to the dosing schedule, which includes 3 doses at ages 2, 4 and 6 months. Two studies have used automated claims...

Descripción completa

Detalles Bibliográficos
Autores principales: Lanes, Stephan, Quinlan, Scott C, Mast, T Christopher, Greenland, Sander, Holick, Crystal N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4406204/
https://www.ncbi.nlm.nih.gov/pubmed/25904968
http://dx.doi.org/10.1186/s12982-015-0027-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4406204/
https://www.ncbi.nlm.nih.gov/pubmed/25904968
http://dx.doi.org/10.1186/s12982-015-0027-6

Ejemplares similares